


Phase 2 Committee Report

- reviewed GCIIG-badged studies; invited new group participation
- reviewed new active agent for future consideration: Triapine
- discussion of LUFT: cervical cancer maintenance of response trial
- G-TAC: GCIIG's multi-drug multi-arm cervical cancer maintenance of response trial

GCIIG-tagged phase 2 trials


- **NSGO lead: FANDANGO**
- **NSGO lead: PALEO**
- **NSGO lead: AVANOVA**
- **NSGO sponsor: OV UMB1**
 - **Randomization 1: SGCTG**
 - **Randomization 2: PMHC**
 - **Randomization 3: NSGO**
- **CCTG lead: STICs and STONES**
- **PMHC lead: NEO**
- **PMHC lead: eVOLVE**

G-TAC: GCIG - Targeted Agents in CxCa



- creation of a “critical mass” of patient experience
- over numerous targeted agents
- more rapid potential accrual and maturation than single trial
- common data and laboratory elements

to volunteer to participate/run an arm/etc: kohne@mail.nih.gov




Interested Groups/Agents:

- **PMHC/CCTG:**
 - Lheureux/Oza; agent: DPX-Survivac
 - CCTG: potential other oral agent
- **G-GOC:** Jhingram; agent: immuno-oncology
- **NSGO:** Mirza; agent: neriparib
- **GEICO:** Oaknin; agent: probable immuno-oncology
- **GOTIC:** following LUFT

to volunteer to participate/run an arm/etc: kohne@mail.nih.gov

Action Items pre-Lisbon:



- Core protocol committee to do:
 - **objective:** protocol precis for agent negotiations
 - **objective:** review protocol draft in Lisbon
- Common data element list:
 - harmonization representative: C. Blattler (PMHC)
 - generate minimum optimal CDE list
 - **objective:** review draft in Lisbon
- Biospecimen collection:
 - **objective:** constitute translational core committee
 - **objective:** develop minimum optimal translational target list for review in Lisbon

to volunteer to participate/run an arm/etc: kohne@mail.nih.gov